Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An International, Placebo-controlled, Double-blind, Randomized Clinical Trial to Evaluate the Efficacy and Safety of 150 mg XAV-19 Infusion, in Patients With Moderate to Severe COVID-19: the EUROXAV Study

NCT04928430 is registered in ClinicalTrials.gov with Xenothera SAS as lead sponsor.

NCT NCT04928430
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04928430 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An International, Placebo-controlled, Double-blind, Randomized Clinical Trial to Evaluate the Efficacy and Safety of 150 mg XAV-19 Infusion, in Patients With Moderate to Severe COVID-19: the EUROXAV Study
Lead sponsor
Xenothera SAS
Phase
Phase 2/3
Overall status
Terminated
Start date
April 28, 2021
Completion date
November 28, 2022
Enrollment
290 (actual)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19